VYCOR MEDICAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VYCOR MEDICAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.38M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $1.45M | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $1.14M | Mar 31, 2017 |
| FY2015 | Dec 31, 2015 | 1.14M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | 1.25M | Mar 30, 2016 |
| FY2014 | Dec 31, 2014 | $1.25M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $1.09M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $1.21M | Apr 7, 2014 |
| FY2012 | Dec 31, 2011 | $971.4K | Apr 1, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.59M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.46M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.22M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.14M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.39M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.51M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.38M | Mar 29, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.32M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.08M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.26M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.01M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.26M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.34M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.16M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.27M | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.4K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($107.2K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($69.7K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($404.9K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($435.7K) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($822.5K) | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | ($796.2K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.38M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.48M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.65M) | Mar 30, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.1K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $40.2K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($306.5K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($436.0K) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($727.4K) | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | ($601.4K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.32M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.31M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.59M) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.3K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.6K | Apr 15, 2025 |
| FY2022 | Dec 31, 2021 | $15.2K | Apr 14, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
| FY2018 | Dec 31, 2017 | $3.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.7K | Mar 30, 2018 |
| FY2015 | Dec 31, 2015 | 71,512 | Mar 30, 2016 |
| FY2016 | Dec 31, 2015 | $71.5K | Mar 31, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.46M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.36M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.20M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.33M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.61M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.68M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.80M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.18M | Mar 27, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.5K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $60.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $29.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($217.0K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $21.4K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($248.8K) | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | ($6.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($260.3K) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($527.4K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($496.9K) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.8K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $38.4K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $62.1K | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $52.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $63.5K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $183.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $57.5K | Mar 30, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $830.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $998.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $992.3K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $860.2K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $935.4K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $986.5K | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.09M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.04M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.45M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.49M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.92M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.69M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.32M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.80M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.33M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.97M | Apr 13, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.69M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($3.33M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($2.94M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $2.40M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($1.98M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | ($1.35M) | Apr 13, 2022 |
| FY2020 | Dec 31, 2018 | ($768.8K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $81.4K | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | ($26.4K) | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.65M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($33.25M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($32.82M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($32.43M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($31.70M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($30.94M) | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | ($29.79M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($28.67M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($26.97M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($25.16M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $105.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $57.3K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $37.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $90.9K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $46.0K | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $60.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $86.5K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $206.2K | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $56.9K | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.37M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 33.37M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 32.63M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 32.53M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 30.82M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 27.43M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | 25.29M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 23.14M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 19.82M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 11.34M | Mar 30, 2018 |